Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin

SAN FRANCISCO, Oct. 17, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company's proprietary biochemical protein synthesis technology platform for the synthesis and manufacturing of novel protein therapeutics will be presented at the BioProduction 2011 conference in Berlin.

Trevor Hallam, Ph.D., chief scientific officer of Sutro, will present the capabilities of the company's platform as a design and production tool for hundreds of variants of potential protein therapeutics, including those with site-specifically incorporated non-natural amino-acids as well as those that cannot be synthesized with conventional technologies. Proteins can be expressed at research scale in a rapid parallel manner in several hours, and the linear scalability of the system allows for seamless and prompt scale up for use in clinical studies.  Sutro is establishing a current Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using their biochemical protein synthesis platform that will be on line in the first half of 2012. The featured presentation will take place at 4:20 p.m. CEST on Oct. 20.

"I am pleased to present Sutro's open, cell-free protein synthesis platform and its application to this broad audience at the BioProduction meeting," said Trevor Hallam, Ph.D. "Our technology platform enables the expression of proteins that cannot be expressed with other expression systems, including novel antibody-drug conjugates and other proteins with site-specific modifications. We are currently establishing our own drug pipeline and are also looking forward to discuss potential collaborations with new partners."

About Sutro Biopharma

Sutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology opens up opportunities to create protein therapeutics that cannot be produced using conventional methods. Sutro's technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once identified, the company can efficiently scale production to commercial levels. In addition to developing its own drug pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies.

Media Contacts:

David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4292
(347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com

SOURCE Sutro Biopharma